Figure of the HARBOUR study

The HARBOUR study, OP-113, is a non-interventional study (NIS), of melphalan flufenamide (melflufen, Pepaxti®) in combination with dexamethasone in patients with relapsed and/or refractory multiple myeloma (RRMM) according to the approved label.

This NIS aims to observe the effects of the use of melflufen, in combination with dexamethasone, in clinical practice in Germany. The patients in this type of study will receive the same treatment and diagnostic procedures as they would have received if they were not included in this study.

The study started in Q4 2023 and is planning to enroll up to 100 patients in Germany in real-life clinical practice.


Read more here: German Clinical Trials Register